Clinical Trial · NCT06916338

Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer

Overview

This study aims to evaluate the diagnostic accuracy (sensitivity, specificity, positive/negative predictive value, and overall accuracy) of 18F-FAPI-04 PET imaging in breast cancer for detecting fibroblast activation protein (FAP)-rich lesions. Additionally, the study will longitudinally monitor dynamic changes in FAP expression levels and tumor size during therapy, including chemotherapy, targeted therapy, or immunotherapy.The non-invasive nature of 18F-FAPI-04 PET addresses limitations of traditional biopsy-dependent stromal evaluation, offering whole-body quantification of tumor microenvironment dynamics to optimize therapeutic decision-making.

Sponsor

The Affiliated Hospital of Qingdao University

Phase

N/A

Contacts

Zhenguang Wang

wangzhenguang@qde.edu.cn

+86-0532-82913318

ClinicalTrials.gov

NCT06916338

Drug / Compound

18F-Labeled FAPI-04

Isotope(s):
Target(s):
  • FAP